Aaron Gardner

Aaron R. Gardner

Partner

Aaron Gardner represents a variety of domestic and foreign companies, including private equity funds and publicly held and private companies in various industries, particularly the life sciences. He represents clients in a wide range of corporate transactions, including mergers and acquisitions, public and private securities offerings, corporate finance, joint ventures and strategic alliances. Mr. Gardner has experience structuring and negotiating intellectual property licenses, development, commercialization and other collaboration agreements, manufacturing and supply agreements, and counseling with respect to other complex business relationships.

Previously, Mr. Gardner was seconded as in-house counsel by a pharmaceutical client of the firm. Mr. Gardner served as senior M&A counsel in the global corporate group, where he advised on transactional matters including a major strategic acquisition and the global divestiture of a portfolio of products including branded pharmaceuticals, generics, diagnostics and over-the-counter medicines. As a result of his tenure as in-house counsel for the client, Mr. Gardner has a real-world understanding of the in-house corporate legal function, and substantial experience counseling corporate executives on a variety of legal and commercial issues.

Experience

  • Lonza, a Switzerland-based pharmaceutical, biotech and specialty ingredients supplier, in the strategic acquisition of California-based InterHealth Nutraceuticals Inc., a portfolio company of Kainos Capital, for up to US$300 million.
  • Sandoz, the generic pharmaceuticals division of Novartis, in a collaboration agreement with biotechnology company MedinCell to develop and commercialize long-acting injectable drug products based on MedinCell's proprietary technology platform for controlled and sustained drug delivery, with a primary focus on oncology.
  • Novartis in a long-term agreement with California-based Thermo Fisher Scientific to develop and commercialize a multi-marker, universal next-generation sequencing (NGS) oncology test to serve as a companion diagnostic for non-small cell lung cancer across multiple drug development programs.
  • Novartis in the acquisition of Admune Therapeutics, a clinical-stage biotechnology company, broadening Novartis' immuno-oncology pipeline.
  • Halifax Capital Partners in the sale of its portfolio company, Caring Brands International, a leading worldwide franchisor of home healthcare services, to Levine Leichtman Capital Partners.
  • Novartis in the sale of the rights to schizophrenia drug Clozaril® in the US and Canada to HLS Therapeutics.
  • Pfizer in a worldwide licensing agreement with OPKO Health Inc., granting Pfizer exclusive rights to develop and commercialize OPKO's long-acting human growth hormone (hGH-CTP) for the treatment of growth hormone deficiency in adults and children, for an upfront payment of US$295 million with up to US$275 million of contingent milestone payments plus undisclosed royalties.
  • Novartis in a master collaboration agreement with QIAGEN N.V. to enable to development and commercialization of companion diagnostics to be paired with existing Novartis products as well as compounds in its development pipeline.
  • Pfizer in the acquisition of InnoPharma, Inc., a privately held sterile product development company focused on developing complex generic and innovative specialty pharmaceutical products in injectable and ophthalmic dosage forms, for an upfront cash payment of US$225 million, with up to US$135 million of contingent milestone payments.
  • Tequila Avión in its agreement to sell a majority stake in the Avión Spirits LLC joint venture to Pernod Ricard USA.

Perspectives

Managing Corruption Risks in Life Sciences and Healthcare M&A
Arnold & Porter Kaye Scholer LLP

Recognition

Law360
Life Sciences "Rising Star" (2016)

Credentials

Education
  • JD, Brooklyn Law School, 2005
  • BS BA, Ohio State University, 2002, cum laude
Admissions
  • New York
  • New Jersey
Overview

Email Disclaimer